Why the study?
Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?
Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?
For patients with a first pulmonary embolism due to a major transient risk factor, therapeutic oral anticoagulation is recommended to be discontinued after 3 months.
Answers are grounded in this paper and cite their sources.
Supports 3-month OAC for first provoked PE; leaves open prospective validation before practice change.
We would like to thank H. Slabbynck and co-workers for their interest in the 2019 European Society of Cardiology/European Respiratory Society guidelines on the diagnosis and management of acute pulmonary embolism (PE), and for their interesting comment on the treatment duration of patients with a high-risk PE secondary to a major transient/reversible risk factor. For patients with first pulmonary embolism secondary to a major transient/reversible risk factor, discontinuation of therapeutic oral anticoagulation is recommended after 3 months http://bit.ly/2Pp68Ti
No takes yet. Share an insight, caveat, or question.
Meyer et al. (2020) conducted a letter in First pulmonary embolism secondary to a major transient/reversible risk factor. Discontinuation of therapeutic oral anticoagulation was evaluated. Discontinuation of therapeutic oral anticoagulation is recommended after 3 months for a first pulmonary embolism secondary to a major transient/reversible risk factor.
Synapse has enriched 10 related papers. Consider them for comparative context: